Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDDTmY2yqEQvF2= MU[0POKhcA>? MlLmZoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ NYO4[2l2OjZ|NUC1OlU>
NP69 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LRUmlEPTB;M{GuOlnDuTJwNUSg{txO M1jtfFI3OjV{NUe1
NP460 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO2TWM2OD1{Mj64OeKyOS5zODFOwG0> M{LpbFI3OjV{NUe1
C666-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF7Lkm1xtE5Njl|IN88US=> MnG5NlYzPTJ3N{W=
C666-1 NETy[4xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVSxNEDDvU1? MXe0PEBp MUXEUXNQ NXvEWJNNe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu NGniTJIzPjJ3MkW3OS=>
C666-1  Mom1SpVv[3Srb36gRZN{[Xl? Ml3QNVAhyrWP NI\ZZXMzPCCq NGC2fYxFVVOR M1fUSIFkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>? MkP0NlYzPTJ3N{W=
C666-1 NVLDbJNPSXCxcITvd4l{KEG|c3H5 M3yyblExKML3TR?= NIPoNJg1QC95MjDo MW\EUXNQ NIK5c2F{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> M{joUFI3OjV{NUe1
A549 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWyOEBp NHzKbYlKSzVyPUG3MlY5KMLzIESuOVIh|ryP NIXwdGczPjF{NUKzNC=>
A549-NTC M{fsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGyOEBp Mn6xTWM2OD1zOT60NkDDuSBzLkm2JO69VQ>? NGLvZWczPjF{NUKzNC=>
A549-920 M3ewVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WwOFI1KGh? MY\JR|UxRTN|Lki1JOKyKDRwOESg{txO MYeyOlEzPTJ|MB?=
CRL-5908 M4PtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XuUFI1KGh? M3XieWlEPTB;M{iuO|EhyrFiMj60N{DPxE1? NET6WpQzPjF{NUKzNC=>
L6 NVzKNpV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rabFExyqEQvF5CpC=> MUSyOE81QC95MjDo NHzx[WxFVVOR MnLlbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v M1\hclI2QDdzN{m0
C2C12 NIfVTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmxNOKh|ryPwrC= M4LQSlI1NzR6L{eyJIg> NUTmTGRjTE2VTx?= M4nPVolvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? Mo\BNlU5PzF5OUS=
MCF-7  M1TB[2Z2dmO2aX;uJGF{e2G7 M3;GdVExyqEQvF2= NH3PS3pFVVOR NFfGfXFqdmirYnn0d{BkgWOuaX6gSFEh[W6mIFTpZ4VzyqB? MknBNlU4ODJ5MEO=
DU4475  Ml3ESpVv[3Srb36gRZN{[Xl? M4G2fFUwOTBxMkCg{txO MWqyOOKhcA>? NXG2NHlo\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>? M3W1R|I2PTR5MUe0
SMMC-7721 NXi2NJNDTnWwY4Tpc44hSXO|YYm= NIfDcpYyOCEQvF2= Mnf1OFghcA>? MWTEUXNQ M4H1XINifXOnczDEUmEhTFOEIHThcYFo\Q>? M{O1SVI2PTR2M{[x
SMMC-7721 NUfiWpRSTnWwY4Tpc44hSXO|YYm= NWL1[GdMOTBizszN NIHifpE1QCCq NGn5[JNFVVOR MlLZbY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=> NGrwd5kzPTV2NEO2NS=>
SMMC-7721 MnvPSpVv[3Srb36gRZN{[Xl? MoHTNVAh|ryP Ml\mOFghcA>? MXrEUXNQ NHHJdnVqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3dCpGlHVkJzwrDtVm5C MoGxNlU2PDR|NkG=
SMMC-7721 M17zNmZ2dmO2aX;uJGF{e2G7 NV[zc21POTBizszN MWqzOkBp MV;EUXNQ M2jtWINifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 M{i3TFI2PTR2M{[x
MCF-7 NF[5V4FHfW6ldHnvckBCe3OjeR?= MlvHNVDDqM7:TR?= MWiwMVI1KGh? MVjpcoR2[2W|IIC1N{BidmRicEKxM2NqeDF? NEDkTWgzPTR6MkO3Ny=>
OVCAR10 NHnpTpBHfW6ldHnvckBCe3OjeR?= NILqcJAyOMLizszN M2m5flIycMLi NVfsW|l[TE2VTx?= MWHpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MUiyOVQzPjV2OB?=
NCI-H23 MV;GeY5kfGmxbjDBd5NigQ>? NF7mOnUyOMLizszN NXK0TGNYOjGqwrC= NULjSFVXTE2VTx?= NFHEeYlqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ NXvaXXRiOjV2Mk[1OFg>
A2780 NX\4SWJ6TnWwY4Tpc44hSXO|YYm= NHnu[IQyOMLizszN MWiyNYjDqA>? NW\vdXk{TE2VTx?= NIjGVYFqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ NEjmO|EzPTR{NkW0PC=>
NCI-H23 NVnCTnpQTnWwY4Tpc44hSXO|YYm= NYLZcIdVOTEEoN88US=> MmfzNlFpyqB? Mnv1SG1UVw>? NWfGXoxN\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> M{fDOlI2PDJ4NUS4
A2780 NVPa[HJGTnWwY4Tpc44hSXO|YYm= NHm3XGoyOMLizszN M3nQW|IycMLi M4WxWmROW09? MV;k[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= NV7V[5k3OjV2Mk[1OFg>
HCT116  MU\GeY5kfGmxbjDBd5NigQ>? NH\TRlQyOCEEtV2= M{ixSVI1KGh? MUXjZZV{\XNiYTDwOVMu\GWyZX7k[Y51KHSndILhdIxwcWRiR{GtZZJz\XO2IHnuJIRqeGyxaXSgTGNVOTF4IHPsc45meyCGMzDhcoQhTDh? NFi1eIYzPTN6MEC1OS=>
MCF-10CA1a M3zNZmZ2dmO2aX;uJGF{e2G7 NI\VcVkyOMLizszN NVrycHF{PDhiaB?= MnnqSG1UVw>? MmLNbY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>? MmTQNlUzPTd5Mkm=
MCF-10A1  MYjGeY5kfGmxbjDBd5NigQ>? NWfHfnAxOTEEoN88US=> MYKyOE81QCCq MXzEUXNQ NUfhcYFVcW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi NVTKU2s6OjV{NUe3Nlk>
MCF-10CA1a MkSySpVv[3Srb36gRZN{[Xl? NIW0cHUyOMLizszN M4HUfFI1KGh? MlPFSG1UVw>? MlzY[IVkemWjc3XzJJRp\SCWR1[t{tI{NWmwZIXj[YQhdVKQQTDs[ZZmdHNib3\NUXAzNMLiTV3QPUwh[W6mwrDpcpRm\3KrbtMg{tLDqDN? MWKyOVI2Pzd{OR?=
MCF-10CA1a NVSzUFJHTnWwY4Tpc44hSXO|YYm= MmjvNVDDqM7:TR?= NEjqWHAzPCCq NV;VbGFDTE2VTx?= NYe3T3JLcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MU[yOVI2Pzd{OR?=
SK-BR-7 MUDGeY5kfGmxbjDBd5NigQ>? MXqxNOKh|ryP NX:0VWlVOjRiaB?= NViyUmVOTE2VTx?= NFHVclBqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M4nzUFI2OjV5N{K5
SUM102PT NHr2d5pHfW6ldHnvckBCe3OjeR?= M33sbFExyqEQvF2= NF7zfmkzPCCq M4DTU2ROW09? NWPWNGVFcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NGfqWmEzPTJ3N{eyPS=>
RAW 264.7 MlvPSpVv[3Srb36gRZN{[Xl? Mn3GNVDDqM7:TR?= Mkn0N|AhdWmw MW\wdoV3\W62czD0bIUheDV|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO= M4XzfFI2OTd{NUS3
RAW 264.7 MVvGeY5kfGmxbjDBd5NigQ>? M{jSZVExyqEQvF2= NG\EVXk{OCCvaX6= NED2fmpz\WS3Y3XzJJRp\SCOUGOtZZVodWWwdHXkJJRp\SCQRj5OvmIhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5 M2jselI2OTd{NUS3
RAW 264.7 MUfGeY5kfGmxbjDBd5NigQ>? NHfHRowyOMLizszN NV3mO5htOzBibXnu M1P3S4lvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> NIiydZgzPTF5MkW0Oy=>
MCF7  MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3S0bVIvPSEEtV2= M4TWWlUh\A>? MlGxSG1UVw>? NFr5[HJ{\W6|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u NWKwfJJtOjVyOEW5NFI>
MCF7  MnTDSpVv[3Srb36gRZN{[Xl? NXG5cpdKOi53INM1US=> MY[0PEBp NFrpVW9FVVOR NHG5WWll\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? NWGzWYVwOjVyOEW5NFI>
ACHN NFq0S2VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGPO[lIxNjVvMUCg{txO NIfJZXQxNTZiZB?= MXzEUXNQ MnjHbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXrzWldkOjVyNke3PFc>
Caki-2 MnTKR4VtdCCYaXHibYxqfHliQYPzZZk> MUmwMlUuOTBizszN NV7uUlVGOC14IHS= MkPDSG1UVw>? M162VolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1OxdlI2ODZ5N{i3
A498 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3P3UlAvPS1zMDFOwG0> MmPkNE03KGR? NHT0UllFVVOR M3j5ZYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoXiNlUxPjd5OEe=
115 MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NY\zSYFmOC53LUGwJO69VQ>? NYXqW21QOC14IHS= MojTSG1UVw>? MlLIbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{fiRVI2ODZ5N{i3
117 M4jUemNmdGxiVnnhZoltcXS7IFHzd4F6 MXSwMlUuOTBizszN NVHDOZRkOC14IHS= NWXNNGk3TE2VTx?= M{OxTIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn:1NlUxPjd5OEe=
ACHN M1HDcGZ2dmO2aX;uJGF{e2G7 MkTLNE42NzFxNTFOwG0> M2Lud|Q5KGh? MV;EUXNQ MnPocIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NFu3N2szPTB4N{e4Oy=>
Caki-2 MV;GeY5kfGmxbjDBd5NigQ>? NYnwOFdvOC53L{GvOUDPxE1? NYni[ZRGPDhiaB?= MkfVSG1UVw>? NUPsOJYydGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NUPTRpc3OjVyNke3PFc>
A498 MYjGeY5kfGmxbjDBd5NigQ>? NUi5fI5VOC53L{GvOUDPxE1? M3nwZlQ5KGh? M3f1SWROW09? MkfacIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? MojQNlUxPjd5OEe=
115 M{PTOWZ2dmO2aX;uJGF{e2G7 MYWwMlUwOS93IN88US=> MWO0PEBp MoLzSG1UVw>? MnnXcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? MoPsNlUxPjd5OEe=
ACHN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nRXlUh|ryP M3LGb|Q5KGh? M16wdGROW09? MmnybY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MnvmNlUxPjd5OEe=
Caki-2 NVq1Xpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G4NVUh|ryP NHrrTFE1QCCq NIT6cFdFVVOR MoHrbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NXL0TWNuOjVyNke3PFc>
A498 M4GxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3wOUDPxE1? MkLBOFghcA>? M{f4SGROW09? M4LWeYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> M2P2S|I2ODZ5N{i3
115 NVnx[nJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i0SVUh|ryP MoSwOFghcA>? M{KxV2ROW09? M3Tz[olv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MYSyOVA3Pzd6Nx?=
ACHN NWHSW2g5TnWwY4Tpc44hSXO|YYm= NW[4U3BwPSEQvF2= NFnRfGg1QCCq MXHEUXNQ NYqwN2NDcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NEHPOFczPTB4N{e4Oy=>
Caki-2 NYHDbG96TnWwY4Tpc44hSXO|YYm= NHXGZYk2KM7:TR?= MkL2OFghcA>? NIfq[FRFVVOR MW\pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MmqzNlUxPjd5OEe=
A498 M4WxUWZ2dmO2aX;uJGF{e2G7 NWmzOIk{PSEQvF2= MoLrOFghcA>? MoTnSG1UVw>? MW\pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MUSyOVA3Pzd6Nx?=
115 NXy5cotnTnWwY4Tpc44hSXO|YYm= NXjIRoxWPSEQvF2= M4nOWVQ5KGh? NEXx[25FVVOR MmDZbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NVrZS5FyOjVyNke3PFc>
MOLM-13 NHHZZotHfW6ldHnvckBCe3OjeR?= MVq2xsDPxE1? M4LYclAuQCCq NITyO2ZFVVOR M{SxOYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? MWKyOFg5PTB6Mh?=
MOLM-13 MnXuSpVv[3Srb36gRZN{[Xl? M4\s[FbDqM7:TR?= MnXZOkBp MnLDSG1UVw>? MYjlcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly NU\2N|ZNOjR6OEWwPFI>
HepG2 NX\Lb3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLPbnE4OiCq NXTQcYFkTE2VTx?= MkGwTWM2OD1|NT64OkDDuSB{Lkmg{txO MnrmNlQ5QDR6MEm=
HepG2/As NV:4O4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NkBp MXvEUXNQ NFTYWIRKSzVyPU[4MlE{KMLzIEmuOkDPxE1? Mmi5NlQ5QDR6MEm=
SMMC7721 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe3NkBp MXHEUXNQ M2DmWWlEPTB;M{GuNlghyrFiND6yJO69VQ>? MmXWNlQ5QDR6MEm=
SMMC7721/Ac NYrTd29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe3NkBp NFG3e4dFVVOR NYLmOHpiUUN3ME21OU4zOSEEsTC1MlA{KM7:TR?= NVqxW5dnOjR6OES4NFk>
Huh-7 NHzNUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrXO|IhcA>? M4nmSWROW09? NYe3[HNuUUN3ME2zN{46PiEEsTCzMlkh|ryP M1r0UFI1QDh2OEC5
Hep3B MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXaO|IhcA>? NGnHV21FVVOR MVXJR|UxRTJyLkG4JOKyKDFwOESg{txO NID3[3IzPDh6NEiwPS=>
HepG2 NHvWZW1CeG:ydH;zbZMhSXO|YYm= NFq2V2RqdmS3Y3XzJIFxd3C2b4Ppdy=> Mn\pNlQ5QDR6MEm=
SMMC7721 Ml;yRZBweHSxc3nzJGF{e2G7 MU\pcoR2[2W|IHHwc5B1d3Orcx?= NV7Vbnd6OjR6OES4NFk>
Huh-7 M3K4T2Fxd3C2b4Ppd{BCe3OjeR?= NUnkOmxycW6mdXPld{BieG:ydH;zbZM> MoH3NlQ5QDR6MEm=
Hep3B Mk\hRZBweHSxc3nzJGF{e2G7 MljBbY5lfWOnczDhdI9xfG:|aYO= M2TLelI1QDh2OEC5
U2OS  NUTl[oJOTnWwY4Tpc44hSXO|YYm= M4TLbVIxKM7:TR?= M3HyS|I1KGh? NHzTfmJqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX NYnEfGJuOjR6NkeyOVk>
AML2 MmD1RZBweHSxc3nzJGF{e2G7 MknaNk8yOCEQvF2= M2n1V|I1NzR6IHi= NF7KcFFqdmS3Y3XzJIFxd3C2b4Ppdy=> NEi4elkzPDZ3OUe0PS=>
MOML13 MoPWRZBweHSxc3nzJGF{e2G7 NVLMSmw1Oi9zMDFOwG0> NVvJSYQ4OjRxNEigbC=> MofPbY5lfWOnczDhdI9xfG:|aYO= NXzvRVM4OjR4NUm3OFk>
AML2 M2exR2Z2dmO2aX;uJGF{e2G7 NYW4O5FpOTEQvF2= NH7lfJEzNzRiaB?= M2PtRolv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz NXTZ[mRzOjR4NUm3OFk>
AML3 MV3GeY5kfGmxbjDBd5NigQ>? MYexNO69VQ>? MWWyM|QhcA>? MmLNbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NWXuUJI4OjR4NUm3OFk>
MOML13 NV:4S3FJTnWwY4Tpc44hSXO|YYm= NEjFb3IyOM7:TR?= NFfyRmkzNzRiaB?= M{HxR4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz MoHENlQ3PTl5NEm=
BeWo NU\seJR2TnWwY4Tpc44hSXO|YYm= MYKzNEDDvU1? NInzVXczPCCq MlPIbY5kemWjc3XzJJA2OyxiTXTtNkwheDJzIHHu[EBRfW2jIHH0JJRp\SCycn;0[YlvKGyndnXs MkL0NlQ1QThzNUS=
BeWo Mom4RZBweHSxc3nzJGF{e2G7 NEeydXI{OCEEtV2= M3f4PFI1KGh? NILzZ2NqdmO{ZXHz[ZMh[XCxcITvd4l{ NXK1cm55OjR2OUixOVQ>
OCI MVzGeY5kfGmxbjDBd5NigQ>? NVTHWpV4OTBizszN M{W0Z|I1KGh? MYf1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? MVuyOFQ4OzV4Mh?=
MOLM NX:0XJBiTnWwY4Tpc44hSXO|YYm= MlPONVAh|ryP MknQNlQhcA>? Mkf1eZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w M{fZc|I1PDd|NU[y
U2OS  MXjGeY5kfGmxbjDBd5NigQ>? NFnMUG0zOCEQvF2= NFnIe4UzPCCq NHHZUoxqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw NFTafIUzPDN4NkCwOy=>
RKO NXnvVYoxTnWwY4Tpc44hSXO|YYm= NH7oNIczOCEQvF2= MVeyOEBp Mlj3bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? M3ywflI1OzZ4MEC3
U2OS  MkjKSpVv[3Srb36gRZN{[Xl? NILUc5IzOCEQvF2= MV:yOEBp MV3pcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= NGjOXmwzPDN4NkCwOy=>
RKO M3LBNGZ2dmO2aX;uJGF{e2G7 NFy3cGwzOCEQvF2= NH\RdGUzPCCq NGTSfGRqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> NF3ablUzPDN4NkCwOy=>
SMMC-7721  NFSxRlNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXLrbXk{OS5{NT2yNEDPxE1? MWSyOE81QC95MjDo M2jVSmROW09? NULOOnVIcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NInodmozPDJ6NkOxNi=>
HuH-7 NWH0ZZFLS2WubDDWbYFjcWyrdImgRZN{[Xl? NFqzXWoyNjJ3LUKwJO69VQ>? Mmr4NlQwPDhxN{KgbC=> NVTBeYM6TE2VTx?= NGfu[odqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NITXT2wzPDJ6NkOxNi=>
SMMC-7721  MVvBdI9xfG:|aYOgRZN{[Xl? NF;kXYUzOCEQvF2= Mmi0OFghcA>? M2eweGROW09? NIPFT|hqdmS3Y3XzJIFxd3C2b4Ppdy=> MlHsNlQzQDZ|MUK=
HuH-7 NEW1TlBCeG:ydH;zbZMhSXO|YYm= M3LpRVIxKM7:TR?= MVG0PEBp Mk\2SG1UVw>? NU[wdmcycW6mdXPld{BieG:ydH;zbZM> MUCyOFI5PjNzMh?=
SMMC-7721  MULGeY5kfGmxbjDBd5NigQ>? MX6xNEDPxE1? NV7mXVdjOzZiaB?= M3vPUmROW09? NETXXYRld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? NF;lUYUzPDJ6NkOxNi=>
HuH-7 MWXGeY5kfGmxbjDBd5NigQ>? NGPhSJgyOCEQvF2= MWSzOkBp NYXJOXVpTE2VTx?= NHzv[mhld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? M3iyVVI1Ojh4M{Gy
AT2 M4r2UmZ2dmO2aX;uJGF{e2G7 MoXGOU8yOCEQvF2= NYrtVnh2dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MnS3NlQzPDB{MEO=
REH NFT2[GlHfW6ldHnvckBCe3OjeR?= NFnWOVE2NzFyIN88US=> M2Tze4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NYLzSZU{OjR{NECyNFM>
UoCB6 M2r4fWZ2dmO2aX;uJGF{e2G7 M4j0VVUwOTBizszN M3fWboxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NI\sb3gzPDJ2MEKwNy=>
AT2 MnzrR4VtdCCYaXHibYxqfHliQYPzZZk> NWDmbJg2OC1{NTFOwG0> NULWeGdHcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NYfpZ4RGOjR{NECyNFM>
REH MorYR4VtdCCYaXHibYxqfHliQYPzZZk> NH\ROI8xNTJ3IN88US=> M{\RZYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MX[yOFI1ODJyMx?=
UoCB6 MmHXR4VtdCCYaXHibYxqfHliQYPzZZk> MXiwMVI2KM7:TR?= MXzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXPjcpBTOjR{NECyNFM>
A2780 MmTHSpVv[3Srb36gRZN{[Xl? NXL0cFVKPS9zMD:yNEDPxE1? NEDj[VUzPCCq MofaeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NEWwXIYzPDF|NkG0Oy=>
H460 M1PPNGZ2dmO2aX;uJGF{e2G7 NFLaZ5Q2NzFyL{KwJO69VQ>? NH\2eGIzPCCq M4K0S5VxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NFy5NI4zPDF|NkG0Oy=>
Lovo  NX[xenNlTnWwY4Tpc44hSXO|YYm= Mlj5OU8yOC9{MDFOwG0> NYHrcWloOjRiaB?= M4PKNpVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi Ml7DNlQyOzZzNEe=
A2780 NIDFUmxCeG:ydH;zbZMhSXO|YYm= NGrsW2Y2NzFyL{KwJO69VQ>? NF;zW2gzPCCq M1HCRYVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NUDlV|E6OjRzM{[xOFc>
H460 MXzBdI9xfG:|aYOgRZN{[Xl? MVi1M|ExNzJyIN88US=> MUiyOEBp M3ryeYVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MkXjNlQyOzZzNEe=
Lovo  NHm1PYVCeG:ydH;zbZMhSXO|YYm= MXW1M|ExNzJyIN88US=> NFq5TlIzPCCq M4XhO4VvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NFX5[JYzPDF|NkG0Oy=>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID